In8bio News

Buy Rating Reaffirmed for IN8bio Amid Promising Clinical Trials and Strong Pipeline

TipRanksMay 10 22:45

IN8bio Q1 2024 GAAP EPS $(0.20) Misses $(0.18) Estimate

IN8bio (NASDAQ:INAB) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.18) by 11.11 percent.

BenzingaMay 10 04:26

In8bio | 10-Q: Quarterly report

Futu NewsMay 10 04:14 · Announcements

IN8bio 1Q Loss/Shr 20c >INAB

IN8bio 1Q Loss/Shr 20c >INAB

Dow JonesMay 10 04:00

Optimistic Outlook for IN8bio: A Buy Rating Ahead of Key Data Release

TipRanksMay 1 00:15

IN8bio Doses First Patient In Phase 2 Clinical Trial Of INB-400 In Newly Diagnosed Glioblastoma

IN8bio Doses First Patient In Phase 2 Clinical Trial Of INB-400 In Newly Diagnosed Glioblastoma

BenzingaApr 30 18:07

IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an oral presen

In8bioApr 24 12:00

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that William H

In8bioApr 16 12:00

12 Health Care Stocks Moving In Friday's After-Market Session

GainersQilian Intl Hldg Gr (NASDAQ:QLI) stock moved upwards by 50.4% to $1.14 during Friday's after-market session. The company's market cap stands at $40.7 million. Allarity Therapeutics (NASDAQ:ALLR

BenzingaApr 13 04:31

Promising Preclinical Data Underpins Buy Rating for IN8bio's NsCAR Platform

TipRanksApr 12 13:45

ATUS, ATHE and GRFS Among Pre-market Losers

Seeking AlphaApr 11 20:16

IN8bio Price Target Maintained With a $14.00/Share by HC Wainwright & Co.

IN8bio Price Target Maintained With a $14.00/Share by HC Wainwright & Co.

Dow JonesApr 10 23:01

HC Wainwright & Co. Reiterates Buy on IN8bio, Maintains $14 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates IN8bio with a Buy and maintains $14 price target.

Analyst UpgradesApr 10 22:51

HC Wainwright & Co. : The IN8bio (INAB.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $14.00.

HC Wainwright & Co. : The IN8bio (INAB.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $14.00.

Zhitong FinanceApr 10 22:50

Analysts Offer Insights on Healthcare Companies: TRACON Pharmaceuticals (TCON) and IN8bio (INAB)

TipRanksApr 10 22:20

IN8bio Gains After New Preclinical Data for NsCAR-T Cell Therapy Platform

Seeking AlphaApr 10 21:49

IN8bio INAB Preclinical Data; Jaguar JAGX Shareholder Meeting

BioPharmCatalystApr 10 20:24

Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket

Shares of PriceSmart, Inc. (NASDAQ:PSMT) rose sharply in today's pre-market trading as the company posted better-than-expected earnings for its second quarter. The company reported quarterly earnings

BenzingaApr 10 20:12

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

GainersIN8bio (NASDAQ:INAB) stock increased by 47.7% to $1.61 during Wednesday's pre-market session. The market value of their outstanding shares is at $69.6 million. Jaguar Health (NASDAQ:JAGX) share

BenzingaApr 10 20:09

Top Premarket Gainers

Marin Software (MRIN) shares surged 58% in recent Wednesday premarket activity a day after it upgraded its integration with Microsoft (MSFT) Advertising. Jaguar Health (JAGX) stock rose over 34% a day

MT NewswiresApr 10 19:54